-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Raises Price Target to $97

Benzinga·08/07/2026 13:51:29
Listen to the news
Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $95 to $97.